Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
D2.27 - “Chronic Urticaria Following Dental Filling Procedure: A Clinical Evaluation”
D2.28 - When Cross-Reactivity Is Not the Answer: Immediate Multiple Drug Hypersensitivity to Aminopenicillins and Ceftriaxone
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D2.151 - HZ-Y030, an Oral STAT6 Degrader, Attenuates Type 2 Inflammation in Preclinical Asthma Models
D2.152 - Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma
D2.155 - Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases
D2.158 - Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma
D2.149 - Occupational asthma in a tea-packaging worker: a case report
D2.150 - Clinical and functional outcomes after the diagnosis of baker’s asthma: ended vs. reduced exposure
D2.154 - Small airway dysfunction defined by reduced FEF25–75% identifies a distinct clinical phenotype in children with preserved FEV1
D2.156 - Defining the Systemic Boundary Between N-ERD and EGPA: Avoiding Misclassification of Eosinophilic Diseases
D2.157 - Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study
D2.159 - Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download